Sichuan Kelun Biotech (6990)

Currency in HKD
378.00
+0.40(+0.11%)
Closed·

6990 Financial Summary

Key Ratios

P/E Ratio-222.96
Price/Book18.43
Debt / Equity3.83%
Return on Equity-9.46%
Dividend Yield0.00%
EBITDA-163.83M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of CNY (except for per share items)

Analyst Ratings

18 Buy
1 Hold
0 Sell
Ratings:
19 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 330.26
(-12.63% Downside)

Earnings

Latest Release
Apr 17, 2025
EPS / Forecast
-2.59 / -3.27
Revenue / Forecast
550.25M / --
EPS Revisions
Last 90 days

FAQ

What were Sichuan Kelun Biotech's earnings for the latest quarter?

The Sichuan Kelun Biotech EPS (TTM) is -1.20. Sichuan Kelun Biotech reported sales of 550.25, net income of -576.99, and EPS of -2.59 for the latest quarter.

What was Sichuan Kelun Biotech's net income for the latest quarter?

Sichuan Kelun Biotech's net income for the latest quarter was -576.99.

How did Sichuan Kelun Biotech's performance compare year-over-year in the latest quarter?

The company's revenue moved from 1,382.79 in the previous quarter to 550.25 in the latest quarter, and net income moved from 310.23 to -576.99 compared to the previous quarter.

What is Sichuan Kelun Biotech's net profit margin on a TTM basis?

Sichuan Kelun Biotech's trailing twelve months (TTM) net profit margin is -13.80%.

How does Sichuan Kelun Biotech's debt to equity ratio compare to industry standards?

Sichuan Kelun Biotech's total debt-to-equity ratio is 3.83%.

What is Sichuan Kelun Biotech's return on investment on a TTM basis?

Sichuan Kelun Biotech's trailing twelve months (TTM) return on investment (ROI) is -9.46%.

Did Sichuan Kelun Biotech gain or lose cash last quarter?

In the latest quarter, Sichuan Kelun Biotech's net change in cash was -793.79 million.

What were Sichuan Kelun Biotech's total assets and liabilities in the latest quarter?

As of the latest quarter, Sichuan Kelun Biotech reported total assets of 4,268.00 million and total liabilities of 809.84 million.

How has Sichuan Kelun Biotech's total revenue grown this year?

Sichuan Kelun Biotech's total revenue was 1,382.79 in the previous quarter and 550.25 in the latest quarter.

What is Sichuan Kelun Biotech's gross margin on a TTM basis?

Sichuan Kelun Biotech's trailing twelve months (TTM) gross margin is 65.89%.

What was Sichuan Kelun Biotech's revenue per share for the latest quarter?

Sichuan Kelun Biotech's revenue per share for the latest quarter was 3.81.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.